The effects of proteasome inhibitors on bone remodeling in multiple myeloma
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Bone disease is a characteristic feature of multiple myeloma, a malignant plasma cell dyscrasia. In patients with multiple myeloma, the normal process of bone remodeling is dysregulated by aberrant bone marrow plasma cells, resulting in increased bone resorption, prevention of new bone formation, and consequent bone destruction. The ubiquitin–proteasome system, which is hyperactive in patients with multiple myeloma, controls the catabolism of several proteins that regulate bone remodeling. Clinical studies have reported that treatment with the first-in-class proteasome inhibitor bortezomib reduces bone resorption and increases bone formation and bone mineral density in patients with multiple myeloma. Since the introduction of bortezomib in 2003, several next-generation proteasome inhibitors have also been used clinically, including carfilzomib, oprozomib, ixazomib, and delanzomib. This review summarizes the available preclinical and clinical evidence regarding the effect of proteasome inhibitors on bone remodeling in multiple myeloma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978 · cited 1×
“Bone disease, defined as the presence of at least 1 osteolytic bone lesion or diffuse osteoporosis with compression fractures, is a characteristic feature of multiple myeloma (MM).[1] Bone disease occurs in MM because of dysregulated bone remodeling, a process in which MM cells interacting with the bone marrow microen…”
BackgroundWNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
Evidence for osteocyte regulation of bone homeostasis through RANKL expression
Nakashima, T., Hayashi, M., Fukunaga, T., Kurata, K., Oh-hora, M., Feng, J. Q., Bonewald, L. F., Kodama, T., Wutz, A., Wagner, E. F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2452 · Cited by 1,778 · cited 1×
“[18-20] The tight control of bone resorption, once thought to be driven by osteoblasts, has now been shown to be the domain of osteocytes, the most abundant cells in bone that are encased in the mineralized matrix.[21,22] The process of bone remodeling and bone”
BackgroundLam, J., Takeshita, S., Barker, J. E., Kanagawa, O., Ross, F. P., & Teitelbaum, S. L. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11176 · Cited by 1,440 · cited 1×
“In addition to RANK, the expression and /or activity of many other osteoclast-activating factors are altered by MM cells including parathyroid hormonerelated protein (PTHrP),[28] activin,[29] macrophage inflammatory protein-1α,[30] macrophage colony-stimulating factor,[31] monocyte chemoattractant protein 1,[32] stro…”
BackgroundCellular and molecular mechanisms of bone remodeling
Raggatt, L. J., & Partridge, N. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.041087 · Cited by 1,402 · cited 2×
“The structure and integrity of the skeleton is maintained by a tightly coordinated process of bone remodeling.[18,19] In this process, osteoclasts continually resorb damaged bone, which is replaced by new bone synthesized by osteoblasts.”
BackgroundMatrix-embedded cells control osteoclast formation
Xiong, J., Onal, M., Jilka, R. L., Weinstein, R. S., Manolagas, S. C., & O'Brien, C. A. (2011) · Nature Medicine · doi:10.1038/nm.2448 · Cited by 1,304 · cited 1×
“[18-20] The tight control of bone resorption, once thought to be driven by osteoblasts, has now been shown to be the domain of osteocytes, the most abundant cells in bone that are encased in the mineralized matrix.[21,22] The process of bone remodeling and bone”
BackgroundThe Osteocyte: An Endocrine Cell … and More
Dallas, S. L., Prideaux, M., & Bonewald, L. F. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1026 · Cited by 1,042
Buried alive: How osteoblasts become osteocytes
Franz‐Odendaal, T. A., Hall, B. K., & Witten, P. E. (2006) · Developmental Dynamics · doi:10.1002/dvdy.20603 · Cited by 795
Giuliani, N., Bataille, R., Mancini, C., Lazzaretti, M., & Barillé, S. (2001) · Blood · doi:10.1182/blood.v98.13.3527 · Cited by 415
Clinical use of proteasome inhibitors in the treatment of multiple myeloma
Merin, N., & Kelly, K. (2014) · Pharmaceuticals · doi:10.3390/ph8010001 · Cited by 90
Cited by
Fricker, L. D. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023603 · Cited by 309
Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease
Liu, H., He, J., Koh, S. P., Zhong, Y., Liu, Z., Wang, Z., Zhang, Y., Li, Z., Tam, B. T., Lin, P., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau9087 · Cited by 113
Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
Solimando, A. G., Malerba, E., Leone, P., Prete, M., Terragna, C., Cavo, M., & Racanelli, V. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.973836 · Cited by 65
“Based on these findings, the currently available treatment for MM targets both the malignant cells and the MM niche, through the inclusion of proteasome or HDAC inhibitors, which act on stromal cells, osteoclasts, and angiogenesis (42, 43).”
Background
Metadata
- Authors
- Zangari, M., & Suva, L. J.
- Venue
- Bone
- Publisher
- Elsevier BV
- Published
- 2016-05
- Volume
- 86
- Pages
- 131-138
- ISSN
- 1873-2763 (ISSN-L)
- 8756-3282
- OpenAlex
- W2296327819
- Cited by
- 46
- References
- 11
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.